GLP-1 Supply-Demand Forecast 2026-2030: When Does Supply Catch Up With Demand?

Three years ago a patient seeking semaglutide had a one in three chance of finding their dose in stock. Today the branded supply has largely caught up. But "caught up" understates what's happening — the entire industry is racing against a demand wave that, when fully unlocked, is at least 5-10x current prescription volume. This is the article we wrote so patients, journalists, and policy people can stop guessing about whether the medication will be available, and start planning around what we actually know.

We update this forecast monthly. The current version reflects evidence and capacity announcements through April 2026. The full structured forecast data is also available as a machine-readable JSON file — researchers and journalists are welcome to cite or ingest it.

Where we are today (April 2026)

Branded GLP-1 supply has stabilised in the major markets. The FDA removed tirzepatide from its drug shortage list in October 2024 and semaglutide in February 2025. The MHRA, EMA, and other regulators have followed. In day-to-day terms, a US patient with a Wegovy prescription and insurance authorisation can now fill it; a UK patient with a private prescription for Mounjaro can typically obtain it within days; an Indian patient can choose from approximately 15 CDSCO-approved generic semaglutide brands at roughly 10% of the branded import price.

What this means: the Phase 1 supply crisis (2023-2025) is over for branded medication in supplied markets. It does not mean the market is in equilibrium. Demand at current prices is the demand-at-current-prices number. Demand at $40/month — the Indian generic price — is a different and much larger number. We are early in a multi-year process of supply expansion, generic spread, and demand unlock.

The 2023-2025 shortage in context

The first GLP-1 shortage was in many ways predictable and in some ways not. The predictable part: a single-ingredient injectable medication that became a cultural phenomenon was always going to outrun manufacturing capacity. The unpredictable part: the bottleneck was not the active ingredient.

Both Novo Nordisk and Eli Lilly have substantial active pharmaceutical ingredient (API) capacity. Solid-phase peptide synthesis at industrial scale is mature chemistry. The shortage was driven by fill-finish capacity — the sterile manufacturing step where the bulk peptide is filled into vials or, more critically, into the pre-filled disposable injection pens that patients use. Pen and auto-injector manufacturing requires specialised aseptic lines that take 18-36 months to commission and are similar to the production lines that have served the insulin market for decades.

The shortage taught the industry three things. First, fill-finish is the binding constraint, and the industry-wide pen-line capacity built for diabetes is not enough for a market that includes obesity. Second, demand at any reasonable price elasticity is essentially unbounded — there is no "satiation point" at which addressable demand stops growing. Third, the supply chain is geographically concentrated in a small number of facilities, which makes it vulnerable to a single quality event or regulatory action.

Novo Nordisk's manufacturing response

Novo Nordisk has committed in excess of $20 billion to GLP-1 manufacturing capacity expansion over 2023-2027. The most consequential moves:

Catalent acquisition: In February 2024, Novo Holdings acquired Catalent Inc. for approximately $16.5 billion. Three of the acquired fill-finish sites — in Anagni (Italy), Brussels (Belgium), and Bloomington (Indiana) — were transferred to Novo Nordisk to dedicate to semaglutide. This was the single largest fill-finish capacity addition ever made for a single molecule by a single company.

Kalundborg, Denmark: Continued multi-billion-dollar expansion of the company's home API and fill-finish complex, with new lines coming online progressively through 2025-2027.

Clayton, North Carolina: Multi-billion-dollar expansion of the existing Clayton facility to add fill-finish capacity.

Process intensification: Investments in continuous manufacturing and higher-throughput aseptic lines that yield more doses per unit of facility footprint.

The combined effect is that Novo Nordisk's branded semaglutide capacity in 2026 is materially higher than it was in 2023, and the trajectory through 2027 sees further step-changes as the Catalent sites complete their transition.

Eli Lilly's manufacturing response

Eli Lilly is making the equivalent investment for tirzepatide:

Lebanon, Indiana: Two manufacturing campuses announced — the first in April 2022 ($2.1 billion), a second in May 2024 ($5.3 billion). Combined investment exceeds $9 billion. These are API and fill-finish.

Concord, North Carolina ($1 billion+) and Research Triangle Park, North Carolina (multi-billion): Additional API and fill-finish capacity.

Limerick, Ireland: Expansion of the existing Limerick site for biotech and parenteral manufacturing.

Indianapolis: Expansion of the company's home parenteral manufacturing.

By 2027 Lilly's tirzepatide manufacturing capacity is forecast to support the company's "many millions of patients globally" stated ambition. The April 2024 Lilly investor day put combined incretin capex 2020-2025 at $20 billion plus, with further commitments through 2027.

The generic capacity question

While Novo and Lilly build branded capacity, an entirely separate manufacturing base is coming online for generic semaglutide outside the OECD patent zone:

India: Following the March 2026 Indian patent expiry, at least 15 CDSCO-approved generic semaglutide manufacturers have launched. These include Dr Reddy's, Natco, Sun Pharma, Glenmark, Cipla, Lupin, Zydus, Eris, Alkem, Mankind, Torrent, USV, Wockhardt, Biocon, and Aurobindo. Indian peptide manufacturing capacity is large and scalable. Conservative estimates put combined Indian generic capacity at 10-30 million patient-years annually within 18-24 months of launch — far in excess of current Indian domestic demand, with significant export capability to other patent-expired markets.

China: Domestic semaglutide is approved by NMPA from manufacturers including Hangzhou Jiuyuan, Huadong Medicine, and others. China is in the unusual position of being both a large potential domestic market and a peptide manufacturing powerhouse.

Brazil: ANVISA-approved generics from EMS, Eurofarma, and others, with more in the queue. Brazilian capacity primarily serves the domestic market.

Canada and Mexico: Generics in regulatory review at Health Canada and COFEPRIS respectively, with launches expected through 2026-2027.

This generic capacity is not currently legally exportable to the United States, EU, UK, Japan, or Australia, where the composition patent runs to approximately 2031. It is, however, exportable between patent-expired jurisdictions — so Indian generic capacity can serve Brazilian, Canadian (after launch), South African, and other markets where patents have lapsed.

The demand picture is shifting structurally

The supply story is dramatic, but the demand story is the larger force. GLP-1 demand was growing from a weight-loss starting point. It is now expanding into multiple co-morbidity indications, each of which can substantially expand the addressable patient population:

Cardiovascular outcomes: The SELECT trial (Lincoff et al., NEJM November 2023) showed semaglutide 2.4mg reduced major adverse cardiovascular events by 20% in non-diabetic patients with established cardiovascular disease and overweight/obesity. The FDA approved a cardiovascular indication for Wegovy in March 2024. This unlocked broader insurance coverage in the US — many commercial plans that previously excluded weight-loss now cover Wegovy on cardiovascular grounds.

Chronic kidney disease: The FLOW trial (Perkovic et al., NEJM 2024) showed semaglutide reduced kidney disease progression and cardiovascular death in T2D patients with CKD. This expands the diabetes-with-CKD patient pool and provides another reimbursement vector.

Obstructive sleep apnea: The SURMOUNT-OSA trial (Malhotra et al., NEJM 2024) showed tirzepatide significantly reduced sleep apnea severity. The FDA approved Zepbound for moderate-to-severe OSA in adults with obesity in December 2024. Sleep apnea is reimbursed by most insurance.

Heart failure with preserved ejection fraction (HFpEF): The STEP-HFpEF trial showed semaglutide improved heart failure symptoms and exercise capacity in obese HFpEF patients. Label expansion likely.

Alcohol use disorder: Multiple Phase 2 readouts suggest GLP-1 medications may reduce alcohol consumption. Larger trials are underway.

Alzheimer's disease: The EVOKE and EVOKE+ trials (Novo Nordisk, semaglutide in early Alzheimer's) are reading out 2025-2026. If positive, this would be a transformational indication.

Liver disease (MASH/NASH): Semaglutide and tirzepatide both showing benefit in metabolic dysfunction-associated steatohepatitis trials.

Every successful trial adds patients to the addressable pool and adds reimbursement vectors that expand access.

The orforglipron and oral GLP-1 question

Eli Lilly's orforglipron is a small-molecule oral GLP-1 agonist (chemically distinct from peptide GLP-1s like semaglutide and tirzepatide). Phase 3 trial readouts in 2024-2025 demonstrated meaningful weight loss and glycaemic control. If approved (regulatory submissions expected 2025-2026), orforglipron would have several supply-side implications:

Manufacturing: Small-molecule oral medication is dramatically cheaper to manufacture than peptide injectables. The fill-finish bottleneck disappears.

Distribution: Tablets do not require cold chain. They can be shipped through normal pharmacy supply chains globally.

Capacity expansion: Small-molecule capacity can be added much faster than peptide aseptic capacity.

Patient access: No injection barrier, no cold-chain barrier, much simpler prescription fulfilment.

If orforglipron is approved at competitive efficacy, it could shift the supply curve before the 2031 OECD generic wave. Expectations on pricing are uncertain — Lilly will likely price orforglipron at a premium to generic semaglutide and a discount to branded injectables, but the pricing strategy is not yet public.

New molecules in late-stage development

Beyond the marketed semaglutide, tirzepatide, and liraglutide, several next-generation molecules are in late-stage development:

Retatrutide (Eli Lilly): Triple agonist (GIP/GLP-1/glucagon). Phase 3. Early trial data showed weight loss exceeding tirzepatide's. Approval submission likely 2026-2027.

Survodutide (Boehringer Ingelheim / Zealand Pharma): Dual GLP-1/glucagon agonist. Phase 3.

Cagrisema (Novo Nordisk): Combination of cagrilintide and semaglutide. Phase 3 results in late 2024 fell modestly short of expectations but the molecule remains commercially viable.

MariTide (Amgen): Phase 3.

CT-388 (Roche, formerly Carmot): Dual GLP-1/GIP agonist. Phase 2 readouts strong.

Pfizer's danuglipron programme was discontinued in 2025 after liver enzyme elevations and other safety signals — a useful reminder that not every late-stage candidate reaches market.

The 2026-2030 supply-demand projection

The forecast we maintain has the following directional shape:

These ranges are wide on purpose — addressable demand depends heavily on what fraction of the global obesity and obesity-related comorbidity population gets prescribed and reimbursed. The structural pattern is:

Branded supply growth is roughly linear and forecastable (capex is mostly committed).

Generic supply growth in patent-expired markets is faster than linear (low capex per added unit, multiple competitive entrants).

Demand growth is non-linear and depends on policy switches — particularly US Medicare coverage of anti-obesity medication, which would singlehandedly add 50-100 million eligible patients in the US alone.

Three scenarios for when supply meets unlocked demand:

Bull case (supply abundant by 2028): Combined branded + Indian generic capacity ramps faster than expected; orforglipron approves; OECD demand stays gated by insurance. In this scenario branded prices begin to soften before 2031 patent expiry.

Base case (supply meets demand around 2030-2032): Branded capacity continues steady growth; generic Indian capacity scales but remains regional; orforglipron approves and modestly expands access; 2031 OECD generic wave is the inflection.

Bear case (chronic constraint through mid-2030s): US Medicare coverage unlocks; major emerging-market reimbursement (China, Brazil) expands; demand unlock outpaces supply; chronic shortages return in the late 2020s.

Magistra's central case is closer to the base case, with non-trivial probability on the bull case. We do not currently see the bear case as the most likely path, but it would only require one or two demand-unlock policy events to become so.

The 2031 OECD generic wave

The single most important date on the GLP-1 supply-demand calendar is approximately 2031, when the semaglutide composition patent lapses in the United States, EU, UK, Japan, and Australia. Generic supply ramping to serve the largest pharmaceutical markets in the world will reset prices in those markets to roughly 10-20% of branded — the same compression already visible in India.

The 2031 wave will:

Crash branded prices: Novo Nordisk and Eli Lilly have already factored this into their long-range planning. Analyst forecasts assume material price pressure on Wegovy and Ozempic from 2031.

Unlock insurance reimbursement: Insurers that exclude branded weight-loss medication today will reconsider when generic prices make the cost-benefit dramatically different.

Compress the addressable demand curve into actual demand: Many patients who want the medication today but cannot afford it will be able to fill prescriptions.

Pressure Eli Lilly's tirzepatide pricing: Tirzepatide patents extend approximately 5 years beyond semaglutide. Lilly's premium pricing for tirzepatide will be tested as patients have a generic semaglutide alternative at a fraction of the cost.

This is the single largest economic event in the GLP-1 medication ecosystem for the rest of the decade.

What this means for patients

A patient making a treatment decision in 2026 should plan around the following:

Branded supply is no longer a constraint in the US, UK, EU and most major markets. If you have a prescription and can afford the medication (insurance or out-of-pocket), it is available.

Affordability is now the binding constraint, not supply. The 2023-2025 question was "can I get any?". The 2026-2030 question is "can I afford to keep taking it?".

If you are in India, Brazil, or another patent-expired market: generic semaglutide at roughly 10% of branded price is your near-certainty path. Use it.

If you are in the US, UK, or EU and considering long-term therapy: the cost picture improves materially in 2031. If you are stable on your current dose and reimbursed, plan around the lifelong-usage assumption (see our [GLP-1 Economics page](/en/economics) for 10-year cost scenarios).

If orforglipron is approved: it may shift the cost picture earlier than 2031, particularly for patients who prefer oral over injectable.

The supply scenario most worth planning around is base case, not bear case: chronic shortages are unlikely to return through the late 2020s, but a major demand-unlock event (US Medicare coverage being the most consequential) would change that.

What this means for policymakers

The GLP-1 supply-demand picture is a near-textbook case of a medication where access is gated by patent geography rather than physical scarcity. The policy levers that would change the access picture most:

US Medicare coverage of anti-obesity medication (Treat and Reduce Obesity Act): this is the largest unlocked demand-side lever globally.

Compulsory licensing in middle-income countries: Brazil and India have used this mechanism for other medicines. It is legally available for GLP-1 outside the patent zone but politically rarely invoked.

Patent term extensions and evergreening: Novo Nordisk and Eli Lilly have a clear interest in extending patent protection through formulation and combination patents. Watching the formal patent challenges in major markets is part of any serious supply forecast.

Speeding generic regulatory pathways: jurisdictions that streamline ANDA-equivalent processes for biosimilars and complex generics will see faster supply arrival post-2031.

Methodology and data sources

This forecast synthesises:

Manufacturer earnings calls and investor day presentations (Novo Nordisk Q4 2024 and FY2025; Eli Lilly Q4 2024 and FY2025; investor day materials)

Capacity expansion announcements (Catalent acquisition press materials; Lebanon IN announcements; Kalundborg expansion details)

Regulatory filings (FDA shortage list, EMA notices, MHRA bulletins, CDSCO India approvals)

Public clinical trial readouts (SELECT, FLOW, SURMOUNT-OSA, EVOKE and others, all referenced via the New England Journal of Medicine, JAMA, or trial registry)

Sell-side analyst reports (Goldman Sachs, JPMorgan, Morgan Stanley, Citi, Jefferies — the consensus range for 2030 GLP-1 market size sits around $130-200 billion, with Novo and Lilly executives publicly comfortable with the higher end of that range)

Indian generic capacity estimates from Express Pharma, Pharmabiz, and individual manufacturer announcements

We update this forecast at least monthly. Material revisions trigger a dated change-log entry in the structured JSON dataset at `/data/glp1-supply-demand-forecast.json`. Researchers, journalists, and policy analysts are welcome to cite this work; please use the citation format on our GLP-1 Economics page.

---

Magistra Health publishes evidence-based information for patients, physicians, and decision-makers in the GLP-1 ecosystem. This article is part of our GLP-1 Economics hub, which is designed to be the most comprehensive single source on GLP-1 medication economics on the internet. Updates are weekly.

Magistra is not a financial advisor and does not make investment recommendations. The forecast presented here reflects our best reading of public information as of the publication date. Actual outcomes will differ. Magistra does not provide medical advice. If you are considering a GLP-1 medication, please consult a licensed healthcare provider.